BR112021019180A2 - Geração de células nk primárias de receptor de antígeno quimérico (car) para imunoterapia de câncer usando uma combinação de vírus cas9/rnp e aav - Google Patents

Geração de células nk primárias de receptor de antígeno quimérico (car) para imunoterapia de câncer usando uma combinação de vírus cas9/rnp e aav

Info

Publication number
BR112021019180A2
BR112021019180A2 BR112021019180A BR112021019180A BR112021019180A2 BR 112021019180 A2 BR112021019180 A2 BR 112021019180A2 BR 112021019180 A BR112021019180 A BR 112021019180A BR 112021019180 A BR112021019180 A BR 112021019180A BR 112021019180 A2 BR112021019180 A2 BR 112021019180A2
Authority
BR
Brazil
Prior art keywords
cells
cas9
rnp
car
primary
Prior art date
Application number
BR112021019180A
Other languages
English (en)
Inventor
Anthony Lee Dean
Christine Meyer Kathrin
Naeimi Kararoudi Meisam
Shibi Likhite
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of BR112021019180A2 publication Critical patent/BR112021019180A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

geração de células nk primárias de receptor de antígeno quimérico (car) para imunoterapia de câncer usando uma combinação de vírus cas9/rnp e aav. são divulgados métodos para engenheirar geneticamente células usando distribuição viral adenoassociada (aav) de um sistema crispr/cas9 e ribonucleoproteínas para integração. em alguns aspectos, são divulgados aqui plasmídeos aav para realizar os referidos métodos.
BR112021019180A 2019-03-27 2020-03-27 Geração de células nk primárias de receptor de antígeno quimérico (car) para imunoterapia de câncer usando uma combinação de vírus cas9/rnp e aav BR112021019180A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825007P 2019-03-27 2019-03-27
PCT/US2020/025454 WO2020198675A1 (en) 2019-03-27 2020-03-27 Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses

Publications (1)

Publication Number Publication Date
BR112021019180A2 true BR112021019180A2 (pt) 2022-03-03

Family

ID=72611833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019180A BR112021019180A2 (pt) 2019-03-27 2020-03-27 Geração de células nk primárias de receptor de antígeno quimérico (car) para imunoterapia de câncer usando uma combinação de vírus cas9/rnp e aav

Country Status (13)

Country Link
US (1) US20220177917A1 (pt)
EP (1) EP3946432A4 (pt)
JP (1) JP2022527709A (pt)
KR (1) KR20220017887A (pt)
CN (1) CN113891727A (pt)
AU (1) AU2020248097A1 (pt)
BR (1) BR112021019180A2 (pt)
CA (1) CA3135198A1 (pt)
CO (1) CO2021014353A2 (pt)
IL (1) IL286701A (pt)
MX (1) MX2021011782A (pt)
SG (1) SG11202110613SA (pt)
WO (1) WO2020198675A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004811A (es) * 2020-10-26 2023-06-29 Res Institute At Nationwide Children´S Hospital Células nk del receptor de antígeno quimérico (car) y usos de las mismas.
WO2022236174A1 (en) * 2021-05-07 2022-11-10 Washington University In situ car-t therapies, vectors and methods therefor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030799T2 (en) * 2012-07-11 2017-06-28 Sangamo Biosciences Inc Methods and preparations for the treatment of lysosomal storage diseases
MX2016007328A (es) * 2013-12-12 2017-07-19 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
AU2015292811B2 (en) * 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
AU2015330699B2 (en) * 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016186772A2 (en) * 2015-05-16 2016-11-24 Genzyme Corporation Gene editing of deep intronic mutations
WO2016201047A1 (en) * 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
EP3967758A1 (en) * 2015-12-01 2022-03-16 CRISPR Therapeutics AG Materials and methods for treatment of alpha-1 antitrypsin deficiency
WO2018081476A2 (en) * 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of t cell therapy
CA3059793A1 (en) * 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
WO2019005957A1 (en) * 2017-06-30 2019-01-03 Precision Biosciences, Inc. GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE

Also Published As

Publication number Publication date
MX2021011782A (es) 2021-12-10
AU2020248097A1 (en) 2021-11-18
CN113891727A (zh) 2022-01-04
JP2022527709A (ja) 2022-06-03
US20220177917A1 (en) 2022-06-09
CA3135198A1 (en) 2020-10-01
EP3946432A1 (en) 2022-02-09
SG11202110613SA (en) 2021-10-28
CO2021014353A2 (es) 2022-01-17
WO2020198675A1 (en) 2020-10-01
EP3946432A4 (en) 2023-04-05
IL286701A (en) 2021-10-31
KR20220017887A (ko) 2022-02-14

Similar Documents

Publication Publication Date Title
PH12018501453A1 (en) Chimeric proteins and methods of immuno therapy
WO2020092854A3 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
AU2018254566A1 (en) Oncolytic virotherapy and immunotherapy
HRP20201090T1 (hr) Protutijela anti-icos
BR112021019180A2 (pt) Geração de células nk primárias de receptor de antígeno quimérico (car) para imunoterapia de câncer usando uma combinação de vírus cas9/rnp e aav
BR112018067698A2 (pt) células modificadas para imunoterapia
CR20180153A (es) Receptores de antígenes quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
BR112021024127A2 (pt) Adenovírus modificado
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
PE20190477A1 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
BR112015027567A2 (pt) polipeptídeo, sequência de ácido nucleico isolada, célula, método de fornecimento de uma imunidade antitumoral
BR112018002600A2 (pt) células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
AR105433A1 (es) Métodos para mejorar la eficacia y expansión de las células inmunes
AU2016259730A8 (en) Claudin-18.2-specific immunoreceptors and T cell epitopes
EA201791381A1 (ru) Универсальная клетка т-киллер
BR112016016937A8 (pt) partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t
AU2017257169A1 (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus
BR112018012826A2 (pt) método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
WO2019232477A3 (en) Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
MX2020013017A (es) Materiales y metodos para tratar cancer.
AR110632A1 (es) Vectores del adenovirus canino
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
CL2020001992A1 (es) Composiciones de virus adeno-asociadas para la transferencia de genes pah y métodos de uso de los mismos
EP4249075A3 (en) Methods of administering chimeric antigen receptor immunotherapy